discontinue immediately if suspected) Gallbladder disease and cholelithiasis (increased incidence with rapid weight loss) Acute kidney injury (usually secondary to severe dehydration from GI effects) Hypoglycemia (primarily when combined with insulin or sulfonylureas) Thyroid C-cell tumors (observed in rodent studies at clinically relevant exposures
Approved injection sites include the abdomen (5 cm from the navel), outer thigh, and outer upper arm
Clinical Trial Perspectives Retatrutide clinical trials primarily investigate its safety, tolerability, and efficacy in addressing obesity and metabolic conditions
Patients who suspect their medication has been stored improperly should consult their healthcare provider or pharmacist before administration
People who track carefully often discover that their headaches peak in weeks two through four of a new dose and then decline, a pattern that would be invisible without systematic recording
Please refer to the Tirzepatide section above for complete safety information